BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Read RL, Thompson JF. Managing in-transit melanoma metastases in the new era of effective systemic therapies for melanoma. Expert Review of Clinical Pharmacology 2019;12:1107-19. [DOI: 10.1080/17512433.2019.1689121] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
Number Citing Articles
1 Queiroz MM, Bertolli E, Belfort FA, Munhoz RR. Management of In-Transit Metastases. Curr Oncol Rep 2022. [PMID: 35192119 DOI: 10.1007/s11912-022-01216-0] [Reference Citation Analysis]
2 Oya K, Nakamura Y, Zhenjie Z, Tanaka R, Okiyama N, Ichimura Y, Ishitsuka Y, Saito A, Kubota N, Watanabe R, Tahara H, Fujimoto M, Fujisawa Y. Combination Treatment of Topical Imiquimod Plus Anti-PD-1 Antibody Exerts Significantly Potent Antitumor Effect. Cancers (Basel) 2021;13:3948. [PMID: 34439104 DOI: 10.3390/cancers13163948] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
3 Guadagni S, Zoras O, Fiorentini G, Masedu F, Lasithiotakis K, Sarti D, Farina AR, Mackay AR, Clementi M. A Prospective Study of Intraarterial Infusion Chemotherapy in Advanced WT BRAF Melanoma Patients. J Surg Res 2021:S0022-4804(21)00381-4. [PMID: 34253376 DOI: 10.1016/j.jss.2021.05.054] [Reference Citation Analysis]
4 Patel A, Carr MJ, Sun J, Zager JS. In-transit metastatic cutaneous melanoma: current management and future directions. Clin Exp Metastasis 2021. [PMID: 33999365 DOI: 10.1007/s10585-021-10100-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
5 Thompson JF, P M Saw R, Dalton JM, Stretch JR, Spillane AJ, Osborne NS, Williams GJ, Lo SN. Treatment of in-transit melanoma metastases using intralesional PV-10. Melanoma Res 2021;31:232-41. [PMID: 33741814 DOI: 10.1097/CMR.0000000000000729] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
6 Gallagher M, Chin KY, MacKenzie-Ross A. Bleomycin electrochemotherapy for the management of locally advanced metastatic melanoma: Two notable clinical cases potentially indicating a greater therapeutic role in the era of targeted and immuno-therapy. JPRAS Open 2020;26:43-8. [PMID: 33102675 DOI: 10.1016/j.jpra.2020.09.007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
7 Dika E, Ravaioli GM, Melotti B, Patrizi A, Veronesi G, Lambertini M, Scarfì F. In transit melanoma and imiquimod: A case of disease progression. Dermatol Ther 2020;33:e13512. [PMID: 32367633 DOI: 10.1111/dth.13512] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
8 Guadagni S, Fiorentini G, Papasotiriou I, Apostolou P, Masedu F, Sarti D, Farina AR, Mackay AR, Clementi M. Circulating tumour cell liquid biopsy in selecting therapy for recurrent cutaneous melanoma with locoregional pelvic metastases: a pilot study. BMC Res Notes 2020;13:176. [PMID: 32204733 DOI: 10.1186/s13104-020-05021-5] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]